Rituximab as Rescue or Add-On Therapy for Relapsing or Refractory Lupus Nephritis: A Systematic Review and Meta-Analysis.
Clin Transl SciSep 30, 2026
Clinical ResearchNephrology
Xiaolong Wang, Shuang Liang, Xiaowei Sun et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy of rituximab (RTX) as rescue or add-on therapy for relapsing or refractory lupus nephritis in 445 patients. The study found pooled complete renal response rates of 33%, 41%, and 42% at 6, 12, and 24 months, respectively, indicating moderate renal response rates in this challenging population.
Key findings
- Pooled complete renal response rates were 33%, 41%, and 42% at 6, 12, and 24 months, respectively.
- Partial renal response rates were 29%, 23%, and 19% at 6, 12, and 24 months.
- Overall renal response rates were 67%, 70%, and 66% at 6, 12, and 24 months.
- Proteinuria decreased by -2.69 g/day-equivalent and serum creatinine decreased by -11.79 μmol/L.
Why it matters
The findings suggest that rituximab may provide moderate renal benefits in patients with relapsing or refractory lupus nephritis, a condition that is often difficult to manage. Understanding these outcomes can help clinicians make informed decisions regarding treatment options.